What is the recommended workup for hyperthyroidism in a patient with thyroid nodules?

Workup for Hyperthyroidism with Thyroid Nodules

Measure TSH first, then free T4 and total T3 to confirm hyperthyroidism, followed by thyroid ultrasound and radioiodine uptake scan to distinguish autonomous nodular disease from Graves disease—this sequence prevents unnecessary imaging and guides definitive treatment selection. 1, 2, 3

Initial Laboratory Assessment

• Start with serum TSH measurement before any imaging, as this is the most cost-effective screening test and determines whether further workup is needed 2
• If TSH is suppressed (<0.1 mIU/L), measure free T4 and total T3 (or free T3) within 4 weeks to confirm overt hyperthyroidism and exclude T3-thyrotoxicosis, which occurs in approximately 12% of patients with autonomous nodules 4, 5
• Repeat TSH measurement for confirmation if initially low, particularly when TSH is between 0.1-0.45 mIU/L, as transient suppression can occur 4

Clinical Pearl: The introduction of sensitive TSH assays has largely replaced older tests like T3-suppression testing and TRH stimulation, which are no longer routinely needed 5

Distinguishing Autonomous Nodular Disease from Graves Disease

Once biochemical hyperthyroidism is confirmed, the critical next step is determining etiology:

Radioiodine Uptake Scan and Scintigraphy

• Obtain iodine-123 thyroid scintigraphy when thyroid nodules are present or etiology is unclear, as this distinguishes autonomous "hot" nodules (high uptake in nodule, suppressed uptake in surrounding tissue) from diffuse Graves disease (diffusely increased uptake) 1, 3, 6
• Iodine-123 is preferred over iodine-131 due to superior imaging quality 1
• Reserve scintigraphy for patients with low TSH levels—only 2.8% of patients with normal or elevated TSH have hyperfunctioning nodules, so scanning can be avoided in 91% of patients with normal TSH 6

Thyroid Ultrasound

• Perform high-resolution thyroid ultrasound as first-line imaging to characterize nodule size, number, and features using ACR TI-RADS risk stratification 2, 7
• Doppler ultrasound can measure thyroid blood flow to separate overactive thyroid (increased flow in Graves disease) from destructive thyroiditis (decreased flow), serving as an alternative when radioiodine scanning is contraindicated 1

Antibody Testing

• Measure TSH receptor antibodies (TRAb) or thyroid-stimulating immunoglobulin (TSI) to confirm or exclude Graves disease—positive antibodies establish Graves disease as the diagnosis 1, 2
• Consider thyroid peroxidase (TPO) antibody testing if autoimmune thyroiditis is suspected 1

Risk Stratification Based on Nodule Characteristics

Size and Toxicity Correlation

• Toxicity rarely develops in autonomous nodules <2.5 cm in diameter and occurs primarily in nodules ≥3 cm, particularly in older patients 8
• Approximately 73.5% of patients with autonomous nodules present with biochemical hyperthyroidism (often subclinical), and an additional 24.4% progress to hyperthyroidism during follow-up 5
• Nodule enlargement occurs in 33% of patients not receiving definitive therapy over approximately 30 months of follow-up 5

Special Considerations for Substernal Extension

• Obtain contrast-enhanced CT of neck and mediastinum when substernal extension is suspected, as CT is superior to ultrasound and MRI for evaluating tracheal compression and mediastinal involvement 2
• Document any aberrant vascular anatomy (e.g., retro-esophageal right subclavian artery predicting non-recurrent laryngeal nerve) and communicate this to the surgeon, as it markedly increases surgical risk 2

Monitoring Strategy for Subclinical Hyperthyroidism

If initial evaluation reveals subclinical hyperthyroidism (TSH <0.45 mIU/L with normal free T4 and T3):

• For TSH 0.1-0.45 mIU/L: Repeat testing at 3-12 month intervals until TSH normalizes or the condition is confirmed stable 4
• For TSH <0.1 mIU/L: Repeat within 4 weeks along with free T4 and total T3; if confirmed, proceed with radioiodine uptake scan to establish etiology 4
• Patients with known nodular thyroid disease require special consideration when exposed to excess iodine (e.g., radiographic contrast), as this can precipitate overt hyperthyroidism 4

Critical Pitfalls to Avoid

• Never initiate thionamides or radioactive iodine for transient thyrotoxicosis (destructive thyroiditis), as it is self-limiting—always obtain uptake studies before definitive treatment in ambiguous cases 1
• Do not rely on fine-needle aspiration alone when functional status is unclear—14% of nodules without definitive FNA are hyperfunctioning, warranting scintigraphy when TSH is suppressed 6
• Avoid prolonged antithyroid drug therapy for toxic multinodular goiter expecting remission, as spontaneous resolution is rare and definitive therapy (surgery or radioiodine) is recommended 2, 5

Treatment Implications Based on Etiology

Autonomous Nodular Disease (Toxic Adenoma or Toxic Multinodular Goiter)

• Definitive therapy options include radioiodine ablation or surgery, with cure rates >95% and hypothyroidism risk of approximately 25% 5
• Surgery is preferred for compressive symptoms, substernal extension, or when RAI is less effective 2

Graves Disease

• Treatment options include antithyroid drugs, radioiodine, or surgery, with choice individualized based on patient factors 3

The key distinction: Autonomous nodular disease represents TSH-independent hyperfunction that rarely remits spontaneously, whereas Graves disease is autoimmune-mediated and may achieve remission with antithyroid drugs 2, 5